AKAlexander Klosovsky

Alexander Klosovsky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexander Klosovsky has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Use of Point-of-Care Handheld Ultrasound for Splenomegaly in United States–Bound Refugees: A Novel Technology with Far-Reaching Implications

    by Tim Kummer, Alexandra M. Medley, Alexander Klosovsky, Erin Mann, Patricia Mburu, Karen Ekernas, Betty Bonass, Jacob C. Stauffer, Stewart Walukaga, Michelle Weinberg, et al.

    Ultrasound (US) is an invaluable clinical tool. New point-of-care US technology holds great promise for hard-to-reach and mobile populations such as refugees. The implementation of US in unique and challenging settings has been hindered by cost, fragility of equipment, need for uninterrupted electricity, training, and difficulty in sharing data/image files impeding quality assurance. The recent development of more flexible, durable, high-quality, low-cost, handheld US technology has offered increased potential to address many of these barriers. We describe a pilot program using a new point-of-care US technology to identify and monitor splenomegaly in United States–bound Congolese refugees. This experience and model may hold lessons for planning and development of similar approaches in other hard-to-reach mobile populations.

  • Open Access

    Prevalence of Malaria Parasite Infections among U.S.-Bound Congolese Refugees with and without Splenomegaly

    by Moses Mwesigwa, Jessica L. Webster, Sam Lubwama Nsobya, Alexander Rowan, Mukunda Singh Basnet, Christina R. Phares, Michelle Weinberg, Alexander Klosovsky, Marwan Naoum, Philip J. Rosenthal, et al.

    All U.S.-bound refugees from sub-Saharan Africa receive presumptive antimalarial treatment before departing for the United States. Among U.S.-bound Congolese refugees, breakthrough malaria cases and persistent splenomegaly have been reported. In response, an enhanced malaria diagnostic program was instituted. Here, we report the prevalence of plasmodial infection among 803 U.S.-bound Congolese refugees who received enhanced diagnostics. Infections by either rapid diagnostic test (RDT) or PCR were detected in 187 (23%) refugees, with 78 (10%) by RDT only, 35 (4%) by PCR only, and 74 (9%) by both. Infections identified by PCR included 103 monoinfections (87 Plasmodium falciparum, eight Plasmodium ovale, seven Plasmodium vivax, and one Plasmodium malariae) and six mixed infections. Splenomegaly was associated with malaria detectable by RDT (odds ratio: 1.8, 95% CI: 1.0–3.0), but not by PCR. Splenomegaly was not strongly associated with parasitemia, indicating that active malaria parasitemia is not necessary for splenomegaly.


  • Open Access

    Clinical Sequelae Associated with Unresolved Tropical Splenomegaly in a Cohort of Recently Resettled Congolese Refugees in the United States-Multiple States, 2015-2018

    by Laura Divens Zambrano, Emily Jentes, Christina Phares, Michelle Weinberg, S. Patrick Kachur, Mukunda Singh Basnet, Alexander Klosovsky, Moses Mwesigwa, Marwan Naoum, Samuel Lubwama Nsobya, et al.

    Tropical splenomegaly is often associated with malaria and schistosomiasis. In 2014 and 2015, 145 Congolese refugees in western Uganda diagnosed with splenomegaly during predeparture medical examinations underwent enhanced screening for various etiologies. After anecdotal reports of unresolved splenomegaly and complications after U.S. arrival, patients were reassessed to describe long-term clinical progression after arrival in the United States. Post-arrival medical information was obtained through medical chart abstraction in collaboration with state health partners in nine participating states. We evaluated observed splenomegaly duration and associated clinical sequelae between 130 case patients from eastern Congo and 102 controls through adjusted hierarchical Poisson models, accounting for familial clustering. Of the 130 case patients, 95 (73.1 %) had detectable splenomegaly after arrival. Of the 85 patients with records beyond 6 months, 45 (52.9%) had persistent splenomegaly, with a median persistence of 14.7 months (range 6.0-27.9 months). Of the 112 patients with available results, 65 (58.0%) patients had evidence of malaria infection, and the mean splenomegaly duration did not differ by Plasmodium species. Refugees with splenomegaly on arrival were 43% more likely to have anemia (adjusted relative risk [aRR]: 1.43, 95% CI: 1.04-1.97). Those with persistent splenomegaly were 60% more likely (adjusted relative risk [aRR]: 1.60, 95% CI: 1.15-2.23) to have a hematologic abnormality, particularly thrombocytopenia (aRR: 5.53, 95% CI: 1.73-17.62), and elevated alkaline phosphatase (aRR: 1.57, 95% CI: 1.03-2.40). Many patients experienced persistent splenomegaly, contradicting literature describing resolution after treatment and removal from an endemic setting. Other possible etiologies should be investigated and effective treatment, beyond treatment for malaria and schistosomiasis, explored.


  • Open Access

    Health challenges in refugee resettlement: an innovative multi-sector partnership to improve the continuum of care for resettled refugees

    by Erin M Mann, Alexander Klosovsky, Catherine Yen, Andrew P J Olson, Sarah J Hoffman, Blain Mamo, Ellen A Frerich, Michelle Weinberg, Harith Mayali, Molly McCoy, et al.

    Refugee resettlement is a highly complex process that may hold lessons for the larger realm of migration medicine. 1 As more and more people are displaced by war, climate change, political strife and economic disparities, migration medicine is becoming an increasingly important component of travel medicine. 2 A recent partnership between the International Organization for Migration/United Nations Agency for Migration (IOM), the US Centers for Disease Control and Prevention (CDC), the University of Minnesota (UMN) and other Minnesota-based organizations has evolved to address the medical needs of migrating refugees, particularly those with complex health needs. The goal of the partnership is to improve a fractured health system during the migration process and to build the capacity of IOM and US-based refugee clinicians to improve the continuum of care delivered to refugees. In this article, we describe our experience with this partnership, which may hold lessons for others developing programmes to improve the health of displaced populations during their migration journey.


  • Open Access

    Impact of Enhanced Health Interventions for United States–Bound Refugees: Evaluating Best Practices in Migration Health

    by Tarissa Mitchell, Deborah Lee, Michelle Weinberg, Christina Phares, Nicola James, Kittisak Amornpaisarnloet, Lalita Aumpipat, Gretchen Cooley, Anita Davies, Valerie Daw Tin Shwe, et al.

    With an unprecedented number of displaced persons worldwide, strategies for improving the health of migrating populations are critical. United States–bound refugees undergo a required overseas medical examination to identify inadmissible conditions (e.g., tuberculosis) 2–6 months before resettlement, but it is limited in scope and may miss important, preventable infectious, chronic, or nutritional causes of morbidity. We sought to evaluate the feasibility and health impact of diagnosis and management of such conditions before travel. We offered voluntary testing for intestinal parasites, anemia, and hepatitis B virus infection, to U.S.-bound refugees from three Thailand–Burma border camps. Treatment and preventive measures (e.g., anemia and parasite treatment, vaccination) were initiated before resettlement. United States refugee health partners received overseas results and provided post-arrival medical examination findings. During July 9, 2012 to November 29, 2013, 2,004 refugees aged 0.5–89 years enrolled. Among 463 participants screened for seven intestinal parasites overseas and after arrival, helminthic infections decreased from 67% to 12%. Among 118 with positive Strongyloides-specific antibody responses, the median fluorescent intensity decreased by an average of 81% after treatment. The prevalence of moderate-to-severe anemia (hemoglobin < 10 g/dL) was halved from 14% at baseline to 7% at departure (McNemar P = 0.001). All 191 (10%) hepatitis B–infected participants received counseling and evaluation; uninfected participants were offered vaccination. This evaluation demonstrates that targeted screening, treatment, and prevention services can be conducted during the migration process to improve the health of refugees before resettlement. With more than 250 million migrants globally, this model may offer insights into healthier migration strategies.


  • Open Access

    Partnerships that Facilitate a Refugee's Journey to Wellbeing

    by Nina Marano, Abbey E. Wojno, William M. Stauffer, Michelle Weinberg, Alexander Klosovsky, J. Daniel Ballew, Sharmila Shetty, Susan Cookson, Patricia Walker, Martin S. Cetron

    The current global refugee crisis involves 65.3 million persons who have been displaced from their homes or countries of origin. While escaping immediate harm may be their first priority, displaced people go on to face numerous health risks, including trauma and injuries, malnutrition, infectious diseases, exacerbation of existing chronic diseases, and mental health conditions. This crisis highlights the importance of building capacity among health-care providers, scientists, and laboratorians to understand and respond to the health needs of refugees. The November 2016 American Society of Tropical Medicine and Hygiene (ASTMH) conference in Atlanta will feature an interactive exhibit entitled “The Refugee Journey to Wellbeing” and three symposia about refugee health. The symposia will focus on tropical disease challenges in refugee populations, careers in refugee health, and recent experiences of governmental agencies and nongovernmental organizations in responding to the global refugee crisis. We invite ASTMH attendees to attend the exhibit and symposia and consider contributions they could make to improve refugee health through tropical disease research or clinical endeavors.